Yazar "Yurekli, Y." seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe I-131 labeling of tamoxifen and biodistribution studies in rats(Pergamon-Elsevier Science Ltd, 2008) Muftuler, F. Z. Biber; Unak, P.; Teksoz, S.; Acar, C.; Yolcular, S.; Yurekli, Y.Tamoxifen [TAM ([Z]-2-[4-(1,2-diphenyl-1-di-butenyl)-phenoxy]-N,N-dimethylethanamine)] has been used as an antiestrogen drug for treatment and prevention of human breast cancer. Tamoxifen was labeled with I-131 using iodogen as an oxidizing agent. Mass spectroscopy of the cold standard showed that the labeling occurs in ortho position to the phenyl ether position of TAM as expected. Quality control, radiochemical yield and stability were established using the radioelectrophoresis method. The radiolabeled compound maintained its stability throughout working period of 24 h. Scintigraphic imaging was performed and tissue distribution was determined in Albino Wistar rats. According to biodistribution and imaging experiments the radiolabeled compound presented estrogen receptor (ER) specificity and it was uptaken by endometrium as well as breast tissue. (C) 2007 Elsevier Ltd. All rights reserved.Öğe L-carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostine using Tc-99m DMSA(Springer, 2005) Yurekli, Y.; Unak, P.; Meteoglu, I.; Yenisey, C.; Ertay, T.; Biber, Z.; Medine, I.Öğe Radiopharmaceutical model using Tc-99m- DMSA to evaluate amifostine protection against cisplatin nephrotoxicity in rats(Springer, 2005) Yurekli, Y.; Unak, P.; Ertay, T.; Biber, Z.; Medine, I.; Acar, C.Öğe Radiopharmaceutical model using Tc-99m-MIBI to evaluate amifostine protection against doxorubicin cardiotoxicity in rats(Springer, 2005) Yurekli, Y.; Unak, P.; Ertay, T.; Biber, Z.; Medine, I.; Teksoz, S.Öğe Tc-99m-glucoheptonate-guanine: Synthesis, biodistribution and imaging in animals(Springer, 2008) Unak, P.; Teksoz, S.; Muftuler, F. Z. Biber; Medine, E. I.; Acar, C.; Yurekli, Y.The aim of the current study was to design a nucleotide-based radiopharmaceutical which could be labeled with Tc-99m and to investigate its radiopharmaceutical efficiency and stability. GHA (glucoheptonate) was used as bifunctional chelate. GHA was labeled with Tc-99m by SnCl2 reduction method first, and then G (guanine) was conjugated with Tc-99m-GHA at 90 C. In order to determine its radiopharmaceutical stability, thin layer radio chromatography (TLRC) and electrophoresis were employed. In addition, the results were confirmed using high performance liquid radio chromatography (HPLRC). Scintigraphic imaging was performed on rats with mammary tumors, while tissue distribution was determined on Albino Wistar rats. Labeling yield was found to be over 95% and the labeled complex maintained its stability during the study period. The lipophilicity of the Tc-99m-GHG was measured and the partition coefficient (logP) of the labeled compound calculated. The results demonstrated that the uptake of Tc-99m-GHG (Tc-99m-glucoheptonate-guanine) reached its maximum at 3 hours p.i. in stomach and intestines. Main way of excretion was renal. Hepatobiliary excretion was also observed. In conclusion, Tc-99m-GHG may be useful as a nucleotide-based radiopharmaceutical for in vivo applications.
